Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $10.9 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Financing Activities fell 9556.9% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year decrease of 9092.7%. This contributed to the annual value of $457.7 million for FY2024, which is 10283.47% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities stood at $10.9 million, which was down 9556.9% from $764000.0 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities registered a high of $290.9 million during Q3 2022, and its lowest value of $108000.0 during Q2 2024.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities averaged around $60.6 million, with its median value being $9.2 million (2025).
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities tumbled by 9978.12% in 2021 and then soared by 1520235.29% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities (Quarter) stood at $170000.0 in 2021, then skyrocketed by 15202.35% to $26.0 million in 2022, then skyrocketed by 664.75% to $198.9 million in 2023, then tumbled by 82.14% to $35.5 million in 2024, then crashed by 69.44% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $764000.0 for Q2 2025, and $9.2 million during Q1 2025.